Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. Apontis Pharma AG
  6. News
  7. Summary
    APPH   DE000A3CMGM5

APONTIS PHARMA AG

(APPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

APONTIS PHARMA : marks further success in the roll-out of Single Pill therapy

07/12/2021 | 01:31am EDT

DGAP-News: APONTIS PHARMA AG / Key word(s): Alliance
APONTIS PHARMA marks further success in the roll-out of Single Pill therapy

12.07.2021 / 07:30
The issuer is solely responsible for the content of this announcement.


APONTIS PHARMA marks further success in the roll-out of Single Pill therapy

Monheim am Rhein, 12 July 2021.
APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, continues to achieve success in the roll-out of its own product portfolio.

The therapeutic effectiveness of Single Pills was verified in the study "Effect of Single pill combinations on Treatment Adherence and persistence as well as on clinical and pharmacoeconomic outcomes in the Real-world Treatment of hypertension, coronary heart disease, hyperlipidemia and in secondary prevention of cardiovascular events" (START), which was conducted in 2019. The purpose of the study, based on an anonymized health insurance data set, was to identify any differences in the forms of therapy.

Ultimately, patients benefit from a Single Pill treatment versus a multi pill regimen. Instead of taking several individual medications for a hypertension indication, taking a Single Pill that combines up to three generic active pharmaceutical ingredients provides greater adherence. Therefore, the prescribed medication is taken more reliably when the dosage form is limited to a Single Pill. Single Pill therapy for hypertensive indications has received endorsement from AXA Krankenversicherung. In a letter to the insurants, the insurance company agreed to cover the costs of the use of Single Pill and support its use.

The Single Pill therapy is evidence-based more efficient and ensures a more sustainable treatment success. The results of the START study also showed that the treatment of cardiovascular Single Pill therapy was associated with lower event rates such as stroke and myocardial infarction in German healthcare services. At the same time, fewer hospitalizations of corresponding patients were necessary. In turn, costs for health insurers are reduced and the overall therapy is less invasive.

"Cardiovascular diseases are still the most common cause of death in Germany. With AXA Krankenversicherung's support, we are raising awareness of a proven, more efficient form of Single Pill therapy and focusing our activities on around 22 million diagnosed, adult hypertensive patients in Germany alone. As a result, both patients benefit from more sustainable treatment success and health insurers from lower costs," says Karlheinz Gast, Chief Executive Officer of APONTIS PHARMA AG.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim am Rhein
Deutschland
apontis-pharma.de

APONTIS PHARMA Presse-Kontakt

CROSS ALLIANCE
Sven Pauly
Sara Pinto
ir@apontis-pharma.de
T: +49 89 125 09 0330
www.crossalliance.de



12.07.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: APONTIS PHARMA AG
Alfred-Nobel-Str. 10
40789 Monheim
Germany
E-mail: info@apontis-pharma.de
Internet: https://apontis-pharma.de/
ISIN: DE000A3CMGM5
WKN: A3CMGM
Listed: Regulated Unofficial Market in Frankfurt (Scale)
EQS News ID: 1217386

 
End of News DGAP News Service

1217386  12.07.2021 

fncls.ssp?fn=show_t_gif&application_id=1217386&application_name=news&site_id=zonebourse_sftp

ę EQS 2021
All news about APONTIS PHARMA AG
09/14APONTIS PHARMA : To Launch New Single Pill For Hypertension, Hyperlipidemia
MT
09/14APONTIS PHARMA : announces launch of new Single Pill for more efficient treatment of hyper..
EQ
09/14PRESS RELEASE : APONTIS PHARMA announces launch of new Single Pill for more efficient trea..
DJ
09/14Apontis Pharma AG Announces Launch of New Single Pill for More Efficient Treatment of H..
CI
08/11APONTIS PHARMA : builds on strong position and profitability in first half of 2021 - preli..
EQ
08/11PRESS RELEASE : APONTIS PHARMA builds on strong position and profitability in first half o..
DJ
07/28APONTIS PHARMA : reports accelerated growth in first half of 2021 - Single Pill revenues +..
EQ
07/28PRESS RELEASE : APONTIS PHARMA reports accelerated growth in first half of 2021 - Single P..
DJ
07/28Apontis Pharma AG Provides Earnings Guidance for the Financial Year 2021
CI
07/28Apontis Pharma AG Announces Unaudited Preliminary Earnings Results for the First Half o..
CI
More news
Financials
Sales 2021 49,3 M 57,7 M 57,7 M
Net income 2021 1,55 M 1,82 M 1,82 M
Net cash 2021 27,5 M 32,2 M 32,2 M
P/E ratio 2021 135x
Yield 2021 -
Capitalization 213 M 249 M 249 M
EV / Sales 2021 3,76x
EV / Sales 2022 3,16x
Nbr of Employees 195
Free-Float 100%
Chart APONTIS PHARMA AG
Duration : Period :
Apontis Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 25,00 €
Average target price 36,50 €
Spread / Average Target 46,0%
EPS Revisions
Managers and Directors
Karlheinz Gast Chief Executive Officer
Edin Hadzic Chairman-Supervisory Board
Olaf Randerath Head-Medical Affairs
Olaf Elbracht Member-Supervisory Board
Christopher Friedel Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
APONTIS PHARMA AG0.00%256
JOHNSON & JOHNSON4.75%433 991
ROCHE HOLDING AG10.87%324 441
PFIZER, INC.19.40%247 760
NOVO NORDISK A/S51.58%233 750
ELI LILLY AND COMPANY37.51%210 490